Фиксированная комбинация адреномиметика и холиноблокатора 12-часового действия в новом устройстве доставки: аналитический обзор

Представлен аналитический обзор применения аклидиния, формотерола и сочетания «формотерол/аклидиний» при ХОБЛ при доставке фиксированной комбинации посредством дозирующего порошкового ингалятора Дженуэйр®. Отмечено, что двойная бронходилатация с 12-часовым эффектом имеет свои преимущества, состоящие в быстрой элиминации препаратов с минимальными системными эффектами, значительным влиянием на одышку и скоростные показатели выдоха, в рентабельности применения данного препарата. Доказано, что Дженуэйр® является новым удобным, простым в использовании в любом возрасте порошковым ингалятором с информативным механизмом обратной связи. Все это делает новую фиксированную комбинацию бронхолитиков в инновационном устройстве перспективным средством базисной терапии ХОБЛ.

Загрузить файл статьи в формате PDF

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2018 report, 2018: 123 p.http://www.coldcopd.prg

2. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология, 2014, 24(3): 15-36.

3. Incorvaia C, Montagni M, Makri E, Ridolo E. New combinations in the treatment of COPD: rationale for aclidinium-formoterol. Ther Clin Risk Manag, 2016, 12: 209-215.

4. Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilationin duced bronchoconstriction. Am Rev Respir Dis, 1990, 142(5): 1147-1152.

5. Prat M, Fernández D, Buil MA et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and longacting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3{[hydroxy(di-2-thienyl)ace. J Med Chem, 2009, 52(16): 5076-5092.

6. Gavalda A, Miralpeix M, Ramos I et al. Charac terization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp The, 2009, 331(2): 740-751.

7. Beier J, Kirsten AM, Mrûz R, Segarra R, Chuecos F, Caracta C, Gil EG. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase IIIb Study. COPD, 2013, 10(4): 511-522.

8. Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: A pooled analysis of five phase iii, randomized, placebo-controlled studies. COPD, 2016, 13(6): 669-676.

9. Naline E, Grassin Delyle S, Salvator H, Brollo M, Faisy C, Victoni T, Abrial C, Devillier P. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther, 2018, 49: 46-53.

10. Malerba M, Radaeli A, Santini G, Morjaria J, Mores N, Mondino C, Macis G, Montuschi P. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov, 2018 Apr 4: 1-15. https://doi.org/10.1080/17460441.2018.1455661.

11. Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, Gil EG. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two sixmonth, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res, 2015, 16: 92. https://doi.org/10.1186/s12931-015-0250-2.

12. Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2041-2053.

13. Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res, 2016, 8: 445-456.

14. Singh D, D’Urzo AD, Chuecos F, Muñoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res, 2017, 18(1): 106.

15. Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 34693485.

16. Capel M, Mareque M, Álvarez CJ, Lindner L, Oyagüez I. Cost-Effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig, 2018 Apr 13. https://doi.org/10.1007/s40261018-0646-0. [Epub ahead of print]

17. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J, 2016, 48(4): 1030-1039.

18. Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an indirect treatment comparison. Adv Ther, 2016, 33(3): 379-399.

19. Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2545-2558.

20. der Palen Jv. Genuair(®) in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler. Ther Deliv, 2014, 5(7): 795-806.

21. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, Garcia Gil E. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med, 2009, 103(12): 1832-1837.

22. Krüger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). European Respiratory Journal., 2014, 44: 4635.

23. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration, 2009, 78(3): 322-328.

24. Blasi F, Canonica GW, Centanni S, Mereu C, Bernabei R, Paolisso G, Incalzi RA, Corsico A, Di Marco F, Milanese M, Pagano F, Santus P, Scichilone N, Sumberesi M, Braido F, Baiardini I. Genuair® usability test: Results of a national public survey of the elderly. COPD, 2016, 13(3): 367-371.

25. García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD, 2017, 14(6): 573-580.

26. Bournival R, Coutu R, Goettel N, Yang CD, Cantin-Lafleur A, Lemieux C, Lévesque AM, Patenaude-Monette JF, Roy FO, Blais L, Arbour F, Fillion A, Beauchesne MF. Preferences and inhalation techniques for inhaler devices used by patients with chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv, 2017 Dec 5. https://doi.org/10.1089/jamp.2017.1409.

27. Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey Int J Chron Obstruct Pulmon Dis, 2018, 13: 695-702.

28. Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1565-1577.